Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Toothbrushing, Dental Plaque, Parent-Child Relations, Oral Hygiene, Dental Caries
Interventions: Fixed Incentive, Drawing Incentive; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Months to 42 Months
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Diabetes Mellitus
Interventions: JTT-252 or Placebo, JTT-252; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Austin, Texas

Conditions: Altruism, Behavior, Emotions
Interventions: Kindness Media; Other
Lead sponsor: Envision Kindness Inc; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New London, Connecticut

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ziv-aflibercept; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 6
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more

Conditions: Chronic Weight Management
Interventions: ASC36 tablets, for oral use, ASC36 placebo tablets; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Hand-Foot Skin Reaction (HFSR)
Interventions: OQL011, Vehicle Ointment; Drug
Lead sponsor: OnQuality Pharmaceuticals (USA) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Goodyear, Arizona • Whittier, California • Aurora, Colorado + 12 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Sitagliptin, Placebo Oral Tablet; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 13 Years to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity
Interventions: AMG 786, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Tustin, California • Aventura, Florida • Miami, Florida

Conditions: Facial Rejuvenation
Interventions: Platelet Rich Therapy (PRT); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Xanomeline/ Trospium Chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Lenexa, Kansas • San Antonio, Texas

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Healthy Volunteer
Interventions: ABBV-CLS-616, Placebo, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Chronic Lower Limb Pain
Interventions: AXIUM Neurostimulator System, Control Spinal Cord Stimulation Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Aptos, California • Carlsbad, California + 19 more

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Atlanta, Georgia + 9 more

Conditions: Healthy Participants
Interventions: BMS-986196, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
Interventions: Nivolumab, Epacadostat, Chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more

Conditions: Dry Age-related Macular Degeneration
Interventions: GT005; Drug
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Huntington Beach, California • Palo Alto, California + 29 more

Conditions: Healthy Volunteers
Interventions: MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Marlton, New Jersey • Austin, Texas

Conditions: Healthy, Liver Diseases, Obesity
Interventions: BI 456906; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Chandler, Arizona • Fort Myers, Florida • Sarasota, Florida + 1 more

Conditions: Advanced Solid Tumors
Interventions: M4076; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Type I Diabetes
Interventions: OPT101, OPT101 Placebo to Match (PTM); Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Walnut Creek, California • Aurora, Colorado + 2 more

Conditions: Multiple Myeloma
Interventions: Siltuximab, Bortezomib, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 11
States / cities: Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 49
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 44 more

Search by objective public record fields.

BEhavioral EConomics for Oral Health iNnovation Pilot Trial

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Impact of Kindness Videos in Health Care Settings

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Sitagliptin Dose Determination Study

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Platelet Rich Therapy for Facial Rejuvenation

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

A Safety and Effectiveness Trial of Spinal Cord Stimulation of the Dorsal Root Ganglion for Chronic Lower Limb Pain

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1